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Abstract
Background
Barrett’s esophagus (BE) is a commonly undiagnosed condition that predisposes to
esophageal adenocarcinoma. Routine endoscopic screening for BE is not recommended
because of the burden this would impose on the health care system. The objective of this
study was to determine whether a novel approach using a minimally invasive cell sampling
device, the Cytosponge, coupled with immunohistochemical staining for the biomarker
Trefoil Factor 3 (TFF3), could be used to identify patients who warrant endoscopy to
diagnose BE.
Methods and Findings
A case–control study was performed across 11 UK hospitals between July 2011 and
December 2013. In total, 1,110 individuals comprising 463 controls with dyspepsia and
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reflux symptoms and 647 BE cases swallowed a Cytosponge prior to endoscopy. The
primary outcome measures were to evaluate the safety, acceptability, and accuracy of the
Cytosponge-TFF3 test compared with endoscopy and biopsy.
In all, 1,042 (93.9%) patients successfully swallowed the Cytosponge, and no serious
adverse events were attributed to the device. The Cytosponge was rated favorably, using
a visual analogue scale, compared with endoscopy (p< 0.001), and patients who were
not sedated for endoscopy were more likely to rate the Cytosponge higher than endoscopy
(Mann-Whitney test, p< 0.001). The overall sensitivity of the test was 79.9% (95% CI
76.4%–83.0%), increasing to 87.2% (95% CI 83.0%–90.6%) for patients with3 cm of
circumferential BE, known to confer a higher cancer risk. The sensitivity increased to 89.7%
(95% CI 82.3%–94.8%) in 107 patients who swallowed the device twice during the study
course. There was no loss of sensitivity in patients with dysplasia. The specificity for diag-
nosing BE was 92.4% (95% CI 89.5%–94.7%). The case–control design of the study
means that the results are not generalizable to a primary care population. Another limitation
is that the acceptability data were limited to a single measure.
Conclusions
The Cytosponge-TFF3 test is safe and acceptable, and has accuracy comparable to other
screening tests. This test may be a simple and inexpensive approach to identify patients
with reflux symptoms who warrant endoscopy to diagnose BE.
Introduction
It is estimated that 5% to 15% of adults in the Western world suffer from reflux symptoms [1],
and this is the commonest physician diagnosis for gastrointestinal consultations, accounting
for 9 million physician consultations in the US in 2009 [2]. On the other hand, many individu-
als with recurrent reflux symptoms do not consult their doctor and hence remain uninvesti-
gated. Endoscopy is performed to justify and tailor the prescription of acid-suppressant
medications, to identify early esophageal adenocarcinoma that has not yet advanced sufficient-
ly to cause weight loss or other alarm symptoms, and to diagnose the pre-malignant precursor
for esophageal adenocarcinoma called Barrett’s esophagus (BE). A diagnosis of BE will be
found in up to 25% of those undergoing endoscopy, depending on the severity of the symptoms
and the age and sex of the individual [3–7]. The majority of individuals with BE are undiag-
nosed [8].
The importance of BE lies in its potential to progress to esophageal adenocarcinoma
through intermediate dysplastic stages. Although the absolute risk of malignant progression is
low [9,10], this is a cancer that, according to most recent data from the US Surveillance, Epide-
miology, and End Results registries, has shown a more than 9-fold increase among white men,
with about half succumbing to their cancer within a year. On the other hand, survival rates are
high (>80%) for superficial cancers confined to the mucosa [11].
Thresholds for endoscopy referral have been the subject of vigorous debate. The major US
medical societies and British Society of Gastroenterology recommend endoscopic screening for
patients with multiple risk factors for esophageal adenocarcinoma, i.e., reflux symptoms, male,
age above 50, high body mass index (BMI), and high waist-to-hip ratio [12,13]. Once diag-
nosed, patients with BE generally enter a surveillance program. Although the merits of surveil-
lance are controversial [12,14–16], there are now strong data to support endoscopic treatment
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for individuals with low and high grade dysplasia, as well as intra-mucosal carcinoma, as a
cancer prevention strategy [17–19].
Hence, there is a renewed interest in determining whether a more systematic diagnosis of
BE coupled with endoscopic therapy could lead to lower mortality from esophageal adenocar-
cinoma. Endoscopic screening for all patients with reflux symptoms would not be affordable or
justifiable for most health care systems. There is therefore a need for a more systematic, cost-
effective, and patient-friendly diagnostic test for BE. We have developed a minimally invasive
non-endoscopic cell collection device, called the Cytosponge, coupled with immunohistochem-
ical staining for a single biomarker, Trefoil Factor 3 (TFF3), that could provide such a test. The
device was piloted previously and consists of a 30-mm polyurethane sponge, contained within
a capsule, which is attached to a string (S1 Fig.). The capsule is swallowed and dissolves within
the stomach after 3–5 min. The sponge is then retrieved by pulling on the string, thus collecting
cells on its return passage along the esophagus [20,21]. Analysis of the cell specimen for TFF3
expression provides an objective, binary read-out of the presence or absence of BE. This bio-
marker was ascertained from a gene expression study designed to distinguish between BE cells
and those from the gastric cardia, squamous esophagus, and oropharynx, which are serially
sampled by the Cytosponge as it is retrieved [21]. The current study described herein takes the
previous work from a proof of concept to a case–control study powered to obtain accurate
estimates of sensitivity and specificity while ensuring that the procedure remains well accepted
and safe in a larger cohort of patients.
Methods
Study Design and Oversight
We conducted a case–control study to determine the sensitivity and specificity of the Cytos-
ponge-TFF3 test for the detection of BE compared with endoscopy and biopsy as the reference
standard (see S1 Protocol). The study was conducted according to the standards of the STARD
statement for reporting studies of diagnostic accuracy (http://www.stard-statement.org/; see S1
Checklist). The UKMedicines and Healthcare Products Regulatory Agency approved use of
the Cytosponge (Medical Research Council, London, UK) for this trial provided that we con-
tinued to collect safety data. Ethics approval was obtained from the East of England–Cam-
bridge Central Research Ethics Committee (No: 10/H0308/71) and registered in the UK
Clinical Research Network Study Portfolio (9461). Individual written informed consent was
obtained for each patient.
Study Participants and Setting
Consecutive patients due to attend endoscopy for a clinically indicated procedure were re-
cruited. Cases were individuals with a previous diagnosis of BE attending for their monitoring
endoscopy. BE was defined as endoscopically visible columnar-lined esophagus that measured
at least 1 cm circumferentially or at least 3 cm in non-circumferential tongues (Prague classifi-
cationC1 orM3), with documented histopathological evidence of intestinal metaplasia
(IM) on at least one biopsy in the course of their endoscopic history. Controls were individuals
referred to endoscopy because of dyspepsia and/or reflux symptoms. Participants who were
initially enrolled as control patients but were then diagnosed with BE at endoscopy (n = 13)
were crossed over to the case arm. Participants were recruited from across 11 centers that were
geographically dispersed across the UK (S1 Table). We included four tertiary referral centers
for BE (Cambridge, University College London, Newcastle, and Nottingham) to enrich for
cases of BE with dysplasia, in case dysplasia adversely affected the sensitivity of the
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Cytosponge-TFF3 assay. Exclusion criteria were patients with bleeding diatheses or on antico-
agulant medication, and those with known cirrhosis, varices, or dysphagia.
Overview of Study Procedures
During a single office visit, we collected data on demographics, clinical exposures (alcohol,
tobacco, drugs), and symptoms; administered the Cytosponge; and then performed an endos-
copy procedure. Following each procedure, acceptability measures were collected. The Cytos-
ponge was administered by a research nurse, and the whole process, including instructing the
patient, took less than 10 min. Twenty-seven nurses were involved in administering the device
over the course of the study across the different sites. After retrieval, the Cytosponge was placed
in SurePath Preservative Fluid (TriPath Imaging, Burlington, North Carolina, US) and kept at
4°C until transportation to the laboratory.
BE patients who happened to undergo a second surveillance endoscopy for clinical purposes
during the study period were invited to swallow the Cytosponge again.
Endpoints
The primary outcomes were sensitivity and specificity of the Cytosponge-TFF3 assay for
detecting BE compared with endoscopy, as well as the safety and acceptability of the device.
Secondary endpoints were the sensitivity of the TFF3 screen in patients with dysplasia and in
patients with BE who swallowed the Cytosponge on more than one occasion.
Cytosponge Sample Processing
Anonymized samples were processed to paraffin blocks and cut into consecutively numbered
sections. Immunostaining was carried out on slides 2 and 15 for TFF3 (proprietary monoclonal
antibody; BD Diagnostics, Durham, North Carolina, US) using standard protocols on a BOND-
MAX autostainer (Leica Biosystems, Newcastle upon Tyne, UK) according to GCP/GLP stan-
dards in the Tissue Bank laboratory housed within Addenbrooke's Hospital, Cambridge. One of
two independent researchers (E. W. or C. S. R.) and a gastrointestinal histo-cytopathologist (M.
O.) scored the slides in a binary fashion as either positive (1 TFF3-positive goblet cell) or
negative. The expert histo-cytopathologist had the final say on TFF3 status. The scorers were
unaware of the clinical diagnosis of the patient.
Endoscopy
The gastroscopies were carried out by a local study endoscopist within an hour of the Cytos-
ponge procedure, and patients had the choice of sedation or local anesthetic spray. A strict
protocol was followed. Biopsy samples were taken from the cardia as well as 2 cm above the
squamocolumnar junction in all participants, and in BE cases diagnostic biopsies were collect-
ed following the recommended Seattle surveillance protocol [22]. Diagnostic biopsies were
reviewed locally. Biopsies with a diagnosis of dysplasia were reviewed in an expert consensus
meeting (M. O., M. N., B. D., and P. K.). When reviewing the biopsy data, all of the histo-
cytopathologists were blinded to the result of the Cytosponge test.
Acceptability Measures
Acceptability for both the Cytosponge and endoscopy was recorded by the participant using a
visual analogue scale in which 0 represented the “worst experience ever,” 10 represented the
“best experience ever,” and 5 indicated “neither pleasant nor unpleasant” [20]. This
Cytosponge-TFF3 for Diagnosing Barrett's Esophagus
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acceptability measure was completed after swallowing the Cytosponge and also after the
endoscopy procedure.
Statistical Analysis
Statistical analyses were conducted by the Cancer Prevention Trials Unit (B. V. N. and
P. D. S.). Assuming a sensitivity of 80% and a specificity of 90% for the TFF3 screen, we needed
to recruit at least 600 BE patients and 450 controls to ensure a 95% confidence interval of ap-
proximately ±3%. Statistics for continuous variables were expressed as medians and interquar-
tile ranges (IQRs). The Mann-Whitney test and Kruskal-Wallis test were used to compare
continuous and ordinal variables, respectively, between groups, and Fisher's exact test and the
Cochran-Armitage trend test [23] were used to compare counts between categorical and ordi-
nal variables, respectively. The κ statistic for agreement between the two TFF3 scorers was cal-
culated. Accuracy of the Cytosponge-TFF3 test was reported using Clopper-Pearson exact 95%
CIs [24]. There were no missing data for the Cytosponge-TFF3 test. For the acceptability data,
patients who were unable to swallow the Cytosponge and those who failed to fill in the visual
analogue scale were excluded from the analysis. All reported p-values were two-sided. Statisti-
cal analyses were carried out using Prism V5.01, SPSS version 19, or R version 3.
Modeling of Risk Stratification of TFF3-Positive Patients
We recently demonstrated that analysis for TP53mutations in Cytosponge samples can be
used to diagnose high grade dysplasia (HGD) when compared with samples from patients
without BE and patients with BE who had never developed dysplasia over a median follow-up
of 6 y [25]. To understand the broader context of the Cytosponge-TFF3 test and stratified risk
using detection of TP53mutations, we have modeled this in a hypothetical population of
10,000 individuals attending primary care for investigation of reflux symptoms. We used a sen-
sitivity of 79.9% and a specificity of 92.4% for detection of any length of BE; for TP53mutation
detection we performed the calculations using a sensitivity of 86% (95% CI 65%–96%) and a
specificity of 100% (95% CI 94.6%–100%) for detection of HGD.
Results
Patient Characteristics and Device Safety
In all, 463 controls with dyspepsia and reflux symptoms and 647 BE cases were recruited; Fig. 1
summarizes the flow of these patients through the study. The cases were generally older than
the controls, with a male predominance (male:female ratio 4.0:1.0), as expected for this disease
(Table 1). The median length of the BE segment for the cases was 5 cm (IQR 3–8), and 30%
(176/596) of the cases had a circumferential BE segment of1 cm.
Three serious adverse events were reported under the Good Clinical Practice guidelines,
none of which were attributed to the Cytosponge. One patient had onset of atrial fibrillation
during radiofrequency ablation that was performed at the same time as the study endoscopy.
One patient was admitted for a bleed from a biopsy site, which stopped spontaneously. One pa-
tient was found to have unsuspected esophageal varices during the endoscopy, but no evidence
of bleeding or Cytosponge abrasions were seen. Three days later the patient had a hematemesis,
and the varices were banded. It was not possible to determine the trigger for bleeding in this
case.
In terms of adverse events, 16.7% of patients had oozing of blood from a Cytosponge abra-
sion site (noted by the endoscopist); however, these abrasions did not require any intervention.
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The oozing was at worst similar to that seen at a biopsy collection site. There were anecdotal
reports of a short-lived sore throat.
Procedure Acceptability
93.9% of patients (1,042/1,110) swallowed the Cytosponge successfully. The proportion of
patients who were unable to swallow the device was significantly higher in the case arm than in
the control arm (7.9% versus 3.9%, p = 0.003). Using a fully adjusted logistic regression, in-
creasing BMI was associated with more difficulty swallowing the Cytosponge; however, the age
and gender of the patients had no impact. Of the 6% (68/1,110) of patients who were unable to
swallow the device, 11.8% (8/68) were also unable to tolerate endoscopy.
When asked to rate the Cytosponge procedure using a visual analogue scale for acceptability
with 0 representing the worst experience ever, 5 representing a neutral score, and 10 represent-
ing the best experience ever, 689/746 patients (92.4%) scored the experience as 4 or more, and
729/746 patients (97.7%) gave a score of 3 or more (mildly unpleasant or better), with a median
value of 6 (IQR 5–8; Fig. 2). Overall, the Cytosponge procedure was rated significantly higher
than the endoscopy procedure (Wilcoxon signed rank test, p< 0.001). In all, 258/748 patients
(34.5%) rated the procedures equally, and 276/732 patients (37.8%) preferred the Cytosponge.
Figure 1. Study CONSORT diagram detailing the flow of control and Barrett’s esophagus patients (cases) through the study. Patients who were
unable to swallow the Cytosponge or whose Cytosponge sample failed processing were excluded from the study. Exact numbers of control and BE patients
who successfully completed the study are noted.
doi:10.1371/journal.pmed.1001780.g001
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On the whole, men rated the Cytosponge better than endoscopy (Mann-Whitney test, p =
0.029), and patients who were not sedated for endoscopy were more likely to rate the Cytos-
ponge higher than endoscopy (Mann-Whitney test, p< 0.001).
Diagnostic Accuracy
A diagnosis of BE using the Cytosponge relies on adequate sampling of the esophageal mucosa
and the presence of TFF3 positivity. Fig. 3 shows examples of TFF3 staining for a case with
widespread TFF3 positivity and for a case with a single TFF3-positive goblet cell, which was
also categorized as positive. A negative case is shown for comparison. The κ statistic for agree-
ment between the two TFF3 scorers was 0.945 (95% CI 0.933–0.958), indicating substantial
agreement. Overall the sensitivity and specificity for diagnosing BE according to our definition
(at least 1 cm circumferentially or at least 3 cm in non-circumferential tongues, with IM in
any diagnostic biopsy) were 79.9% (95% CI 76.4%–83.0%; Table 2) and 92.4% (95% CI 89.5%–
94.7%), respectively (raw data available in S2 Table). There were 34 false positives for diagnos-
ing BE (positive according to the Cytosponge-TFF3 test but negative according to endoscopy)
within the 445 control patients who completed the study. None of these patients with false-
positive results had IM of the gastric cardia.
The sensitivity for diagnosing BE increased with the circumferential length of the BE seg-
ment up to 87.2% (95% CI 83.0%–90.6%, Cochran-Armitage trend test, p< 0.001; Table 2),
and TFF3 positivity was not reduced in the presence of dysplasia (Cochran-Armitage trend
test, p = 0.253; Table 2). Furthermore, the sensitivity and specificity were not affected by any of
the clinical covariates, namely, age, gender, BMI, and waist-to-hip ratio (Table 3). A significant
difference in sensitivity, but not specificity, was seen between centers (p< 0.001; S3 Table).
This difference seems to be attributable to different proportions of cases with no columnar
cells on their sample. Once cases with five or fewer columnar cell groups were excluded, the
sensitivity was uniformly high (p = 0.24, sensitivity range 91% to 98%).
Table 1. Demographics of the BEST2 Study patient cohorts.
Variable Controls BE Casesa
Number 463 647
Age (years)—median (IQR) 56 (44–66) 66 (58–73)
Ethnicity—number (percent)
White 428 (92.5%) 626 (96.8%)
Other 34 (7.3%) 12 (1.8%)
Missing data 1 (0.2%) 9 (1.4%)
Male:female ratiob 1.0:1.3 4.0:1.0
BMI—median (IQR) 26.8 (24.0–30.2) 28.1 (25.6–31.2)
Waist-to-hip ratio—median (IQR) 0.88 (0.83–0.94) 0.95 (0.90–0.99)
Hiatus hernia—percent 34.5% 80.6%
Maximum length of BE (cm)—median (IQR) n/a 5 (3–8)
aBE deﬁned as endoscopically visible columnar-lined esophagus that measured at least 1 cm
circumferentially or at least 3 cm in non-circumferential tongues (Prague classiﬁcation C1 or M3).
bSex ratio rounded to the nearest tenth.
n/a, not applicable.
doi:10.1371/journal.pmed.1001780.t001
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Figure 2. Acceptability of endoscopy and the Cytosponge test. Patients were asked to rate the
procedures using a visual analogue acceptability scale after swallowing the Cytosponge and after
endoscopy. The colors representing the different acceptability scores are shown on the right-hand side, with
0 representing the worst experience ever, 5 representing a neutral experience, and 10 representing the best
experience ever. The dotted red line marks the boundary between mildly unpleasant or worse (left of the line,
score of 0–3) and acceptable scores (right of the line, score of 4 or more), for ease of comparison between
the two procedures.
doi:10.1371/journal.pmed.1001780.g002
Figure 3. TFF3 immunohistochemical staining of Cytosponge samples. TFF3 staining was performed
on all Cytosponge samples to test the sensitivity and specificity of the Cytosponge-TFF3 test for diagnosing
BE. TFF3 was scored in a binary fashion, with samples with one or more TFF3-positive goblet cells being
classed as positive. Shown are immunohistochemical images illustrating examples of TFF3-negative and-
positive staining at low magnification (100×) and high magnification (400×).
doi:10.1371/journal.pmed.1001780.g003
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The study design allowed for patients with BE to swallow a second Cytosponge if they
attended for a further clinically indicated endoscopy during the time course of the study. As
shown in Fig. 1, 107/109 patients (98.2%) successfully swallowed the device on a second occa-
sion, and when both Cytosponge-TFF3 test results were considered, the sensitivity increased to
89.7% (95% CI 82.3%–94.8%; Table 2). The time interval between procedures varied depending
on the clinical indication, but this did not obviously affect the result (Mann-Whitney test, p =
0.139).
Table 2. Sensitivity of the Cytosponge-TFF3 in different groups of patients (full dataset in S2 and S3 Tables).
Patients Total Number TFF3 Positive TFF3 Negative Sensitivity (95% CI)
All BE patients (C1 or M3) 596 476 120 79.9% (76.4%–83.0%)
Segment length
C1 533 434 109 79.5% (75.9%–82.9%)
C2 416 349 67 83.9% (80.0%–87.3%)
C3 320 279 41 87.2% (83.0%–90.6%)
Dysplasia
NDBE 372 294 78 79.0% (74.5%–83.0%)
Indeﬁnite for dysplasia 46 34 12 73.9% (58.9%–85.7%)
LGD 77 63 14 80.5% (69.9%–88.7%)
HGD/IMC 101 85 16 84.2% (75.6%–90.7%)
Patients having two Cytosponge tests 107 95 11 89.7% (82.3%–94.8%)
C, Circumferential length; IMC, intramucosal carcinoma; LGD, low grade dysplasia; M, maximal length; NDBE, non-dysplastic BE.
doi:10.1371/journal.pmed.1001780.t002
Table 3. Clinical covariates have no impact on sensitivity and speciﬁcity of the test.
Covariate Sensitivity (95% CI) Cases Speciﬁcity (95% CI) Controls
TFF3 Positive Total TFF3 Negative Total
BMI (kg/m2)
0–25 0.80% (0.72%–0.87%) 101 126 0.93% (0.88%–0.96%) 144 155
25–30 0.80% (0.75%–0.85%) 215 268 0.92% (0.87%–0.96%) 159 172
30+ 0.80% (0.74%–0.85%) 155 194 0.92% (0.85%–0.96%) 101 110
Age (years)
0–54.9 0.78% (0.69%–0.85%) 85 109 0.94% (0.89%–0.97%) 188 201
54.9–64.9 0.81% (0.74%–0.87%) 120 148 0.94% (0.88%–0.98%) 107 114
64.9+ 0.80% (0.75%–0.84%) 271 339 0.90% (0.83%–0.95%) 116 129
Waist-to-hip ratio
0–1 0.81% (0.77%–0.85%) 386 476 0.92% (0.89%–0.95%) 374 405
1–2 0.75% (0.65%–0.83%) 80 107 0.93% (0.78%–0.99%) 28 30
Gender
Male 0.81% (0.77%–0.84%) 384 475 0.91% (0.86%–0.94%) 177 195
Female 0.76% (0.67%–0.83%) 92 121 0.94% (0.90%–0.97%) 234 249
Overall 0.80% (0.76%–0.83%) 476 596 0.92% (0.90%–0.95%) 411 445
doi:10.1371/journal.pmed.1001780.t003
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Modeling of Risk Stratification of TFF3-Positive Patients
Risk stratification of TFF3-positive patients could be achieved through the addition of screen-
ing for further molecular markers in the same Cytosponge sample, and this strategy has the
potential to significantly reduce the proportion of TFF3-positive patients who would require
endoscopy. Indeed, using an exquisitely sensitive (down to an allele fraction of 0.6%) next-
generation sequencing approach, we recently demonstrated that screening for TP53mutations
in Cytosponge samples can be used to diagnose HGD [25]. We modeled risk stratification in a
population of 10,000 individuals offered the Cytosponge-TFF3 test (Fig. 4). In this population,
we would expect 974 (9.8%) patients to test TFF3 positive. Of these, 737 would be false posi-
tives, and following TP53 testing, between zero and 40 patients would require endoscopy.
Those testing negative for TP53mutations would be scheduled for a repeat Cytosponge, ex-
pected to be between 2 and 5 y later, but the optimal interval is still to be determined. Similarly,
for the true TFF3-positive patients with BE (prevalence 3%), between two and 14 cases would
test positive for TP53mutations, and approximately two of these would be confirmed dysplas-
tic at endoscopy. Hence, following risk stratification, the endoscopy burden in the TFF3-
positive arm would be significantly reduced from 974 to between two and 54 cases. On the
other hand, one would expect 9,026 patients to test TFF3 negative, of which 63 would be false
negatives. If sensitivity was felt to be paramount and these patients were given a second
Figure 4. Modeling of Cytosponge-TFF3 testing and risk stratification in the primary care population with reflux symptoms. Extrapolation of findings
to a hypothetical population of 10,000 individuals with reflux symptoms using a sensitivity and specificity of 79.9% and 92.4%, respectively, for the TFF3
screen, and a sensitivity and specificity of 86% (95%CI of 65%–96%) and 100% (95%CI of 94.6%–100%), respectively, for TP53mutation screening for
detection of HGD. The assumed prevalence of BE was 3%. In patients found to be high risk, endoscopy within 6–8 wk would be recommended. For low-risk
patients, a repeat Cytosponge-TFF3 test would be performed at an interval of several years (exact timing to be determined) in case they had become TP53
positive over this time period. In the TFF3-negative arm, the repeat Cytosponge testing might not be necessary. If it took place, repeat testing would be
recommended within 6 to 8 wk of the delivery of the TFF3-negative results.
doi:10.1371/journal.pmed.1001780.g004
Cytosponge-TFF3 for Diagnosing Barrett's Esophagus
PLOSMedicine | DOI:10.1371/journal.pmed.1001780 January 29, 2015 10 / 19
Cytosponge-TFF3 test, then one would find another 33 true positives at the expense of 681
false positives (based on our repeat Cytosponge-TFF3 test data). However, after risk stratifica-
tion of these positive cases using TP53 sequencing, again the number of endoscopies would be
dramatically reduced to between two and 39 (numbers not shown in Fig. 4).
Discussion
The Cytosponge-TFF3 test is safe and generally acceptable to patients with symptomatic reflux
or dyspepsia undergoing investigation, and for those patients with BE undergoing surveillance.
The test has a sensitivity of around 80% for diagnosing BE; sensitivity increases with BE seg-
ment length and is not compromised in the presence of dysplasia. The specificity of the test
is 92%.
Sensitivity of the Cytosponge-TFF3 Test
In the previous pilot study in which the primary endpoints were feasibility, safety, and accept-
ability, 504 patients were recruited [20]. Although not powered for accuracy, the sensitivity
and specificity obtained in this initial study were 73.3% (95% CI 44.9%–92.2%) and 93.8%
(95% CI 91.3%–95.8%) for1 cm circumferential columnar epithelium for 15/501 patients
with BE. Hence, it is very encouraging that in this adequately powered study, the overall sensi-
tivity of the test has improved, with tighter confidence intervals (79.9%, 95% CI 76.4%–83.0%)
and a similar specificity of 92.4% (95% CI 89.5%–94.7%). In both studies, the sensitivity in-
creased with the length of the BE segment. This is highly relevant given the documented in-
crease in cancer risk with longer BE segments [26,27]. This finding has been further confirmed
by an analysis of over 1,000 cases that demonstrated an annual incidence of esophageal adeno-
carcinoma of 0.32% per year in patients with BE segments of 3 cm or more, compared with an
annual esophageal adenocarcinoma risk of 0.04% for patients with BE segments<3 cm and
0.01% for patients with ultra-short BE segments [28].
The Cytosponge-TFF3 test sensitivity for diagnosing BE increased to nearly 90% when the
device was swallowed a second time. The commonest reason for a false-negative test (76%) was
the absence of columnar cells on the specimen, rather than failure of the TFF3 antibody to rec-
ognize BE when columnar cells were present. Hence, in clinical practice, it would be possible to
advise patients with a TFF3-negative test and no or very few columnar cells seen on the speci-
men to attend for a repeat Cytosponge-TFF3 test, similar to being recalled for a repeat cervical
smear because of an inadequate specimen. Alternatively, the Cytosponge-TFF3 test could be
performed twice in everyone, in a manner analogous to the serial fecal occult blood testing un-
dertaken in some countries as part of a colorectal cancer screening program. It is also possible
that the device could be engineered to maximize collection of cells at the
gastroesophageal junction.
False Positives
False positives are also an important consideration for any screening or diagnostic test. Analy-
sis of our Cytosponge-TFF3 test data in which there were 34/445 (7.6%) false positives suggests
that these were not due to IM at the gastric cardia, nor were they due to very short tongues of
BE. Patients with BE tongues of 1 cm or less with no IM present on biopsies were included in
the control cohort as these patients are likely to have irregular Z lines, but there was no correla-
tion between these types of patients with very short Barrett tongues and false-positive TFF3
results (p = 1.0). However, the correlation between false-positive TFF3 results and the presence
ofHelicobacter pylori nearly reached significance, with a p-value of 0.0825. H. pylori infection
may lead to the presence of IM within the stomach, which may have been missed on the gastric
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cardia biopsy used to assess the presence of cardia IM, but which may nevertheless have been
sampled by the Cytosponge. It is also known that up to 10% of patients presenting to endosco-
py for dyspepsia have a diagnosis of gastric IM, a known precursor lesion to gastric cancer [29].
If a portion of these false-positive results are indeed due to gastric IM, it may actually be benefi-
cial to the patients to be made aware of this, especially since an estimated 10% of these patients
will develop gastric cancer. To put these data in context, our false-positive rate of 7.6% com-
pares with the false positive rate of 2%–9% for colorectal screening. The new multi-target
stool DNA test for colorectal cancer screening [30] has an even higher false-positive rate of
10.2%–13.4%, compared with that of the current fecal immunochemical test, which is 3.6%–
5%, although the authors of the multi-target stool DNA test article argue that sensitivity is
more important than specificity. Another relevant comparison is cervical cancer screening,
which has a false-positive rate of 6%–15% [31], where the over-diagnosis of micro-invasive
cancer is considered more than compensated by the prevention of cancer through treatment of
cervical intra-epithelial neoplasia. With the advent of outpatient-based endoscopic therapy for
BE, a similar argument can be applied to BE. Risk stratification could lead to the equivalent
grading as for cervical intra-epithelial neoplasia 1–3.
Acceptability and Implementation of the Test
The acceptability data are very encouraging. The same scale was used in the community-based
pilot study [20], in which the median score was 7 (IQR 5–8) compared with the median of
6 (IQR 5–8) described here. It is likely that the clinical setting may alter patient preferences.
The community setting is usually more familiar and less daunting for patients, and in this
study the individuals were about to have an endoscopy procedure a few minutes later, which
would have influenced their experience.
When considering implementation of a new technology, the logistical considerations are
also important. The Cytosponge procedure was administered in 11 centers by a total of
27 nurses; training occurred via one training visit by the nurse coordinator (I. D.). In terms of
sample logistics, the samples were stored at 4°C and could be kept for several weeks prior to
processing. The sample processing and antibody staining were performed in a laboratory
housed within the hospital pathology department, and as such followed clinical laboratory
standards. Because of the binary nature of the TFF3 scoring, this test would be amenable to au-
tomated image scanning. Overall, this study was conducted using methods relevant to routine
clinical practice, and nothing emerged that would seem to preclude the implementation of
such a diagnostic test.
The Cytosponge-TFF3 test could be used as a first-line diagnostic test in patients with multi-
ple risk factors for BE (as recommended by the major medical society guidelines [13,32,33])
who would otherwise be referred for endoscopy to rule out BE. However, since a previous
modeling study suggested that the Cytosponge-TFF3 test combined with endotherapy for
treating early cancer had cost advantages over endoscopy [34], this approach may open up the
possibility for more systematic diagnosis of a broader subgroup of the population in the future.
Indeed, since only 12% of patients with gastroesophageal reflux disease are currently being
endoscoped, it follows that only a small fraction of BE cases are being diagnosed through the
current referral routes. While the sensitivity of the Cytosponge-TFF3 test is not perfect at 80%
to 90%, depending on length of BE segment and repeat Cytosponge testing, it would allow a
diagnosis in the vast majority of the currently undiagnosed pool of patients, thus enabling the
required step-change to improve mortality of esophageal adenocarcinoma. However, our
modeling is limited to the expected number of BE patients diagnosed and does not estimate the
expected number of patients who would progress to esophageal adenocarcinoma. Further
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modeling would be required to obtain this degree of information. Based on a 5% prevalence of
BE and sensitivity of 80%, the modeled negative and positive predictive values of the test would
be ~98.9% and 34.7%, respectively. However, the positive predictive value depends heavily on
disease prevalence and would decrease to 25.1% for a population with a 3% BE prevalence and
increase to 44.9% for patient populations with more severe reflux symptoms. Hence, the popu-
lation at risk could be tailored further using simple symptoms nomograms [35,36]. These mod-
eled values are favorable compared with current screening tests such as fecal occult blood
testing, cervical smears, and mammography [31,37–38].
While the case–control design was appropriate to obtain accuracy data with narrow confi-
dence intervals, this design has known limitations in terms of the ability to generalize the data
to the primary care population consulting for reflux symptoms. Care must be taken not to ex-
trapolate the negative and positive predictive values directly. In addition, the acceptability data
were limited to a single measure. In the future it will be important to collect more in-depth
qualitative data on acceptability.
Conclusions
The Cytosponge-TFF3 test can diagnose BE in a manner that is acceptable to patients and lo-
gistically feasible across multiple centers. This test may substantially lower the threshold for
investigating patients with reflux, as part of a strategy to reduce population mortality from
esophageal adenocarcinoma. Analysis of a full panel of risk-stratification biomarkers enriched
further for dysplasia and applied to this cohort is ongoing, and a randomized controlled trial of
the Cytosponge-TFF3 test compared with the current standard of care for patients with reflux
and dyspepsia symptoms in primary care is in preparation. The data from such studies will be
required prior to implementation of the Cytosponge-TFF3 test on a population level.
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Editors' Summary
Background
Barrett's esophagus is a condition in which the cells lining the esophagus (the tube that
transports food from the mouth to the stomach) change and begin to resemble the cells
lining the intestines. Although some people with Barrett's esophagus complain of burning
indigestion or acid reflux from the stomach into the esophagus, many people have no
symptoms or do not seek medical advice, so the condition often remains undiagnosed.
Long-term acid reflux (gastroesophageal reflux disease), obesity, and being male are all
risk factors for Barrett's esophagus, but the condition's exact cause is unclear. Importantly,
people with Barrett's esophagus are more likely to develop esophageal cancer than people
with a normal esophagus, especially if a long length (segment) of the esophagus is affected
or if the esophagus contains abnormally growing “dysplastic” cells. Although esophageal
cancer is rare in the general population, 1%–5% of people with Barrett's esophagus develop
this type of cancer; about half of people diagnosed with esophageal cancer die within a
year of diagnosis.
WhyWas This Study Done?
Early detection and treatment of esophageal cancer increases an affected individual's
chances of survival. Thus, experts recommend that people with multiple risk factors for
Barrett's esophagus undergo endoscopic screening—a procedure that uses a small camera
attached to a long flexible tube to look for esophageal abnormalities. Once diagnosed, pa-
tients with Barrett's esophagus generally enter an endoscopic surveillance program so that
dysplastic cells can be identified as soon as they appear and removed using endoscopic
surgery or “radiofrequency ablation” to prevent cancer development. However, although
endoscopic screening of everyone with reflux symptoms for Barrett's esophagus could po-
tentially reduce deaths from esophageal cancer, such screening is not affordable for most
health care systems. In this case–control study, the researchers investigate whether a cell
sampling device called the Cytosponge coupled with immunohistochemical staining for
Trefoil Factor 3 (TFF3, a biomarker of Barrett's esophagus) can be used to identify individ-
uals who warrant endoscopic investigation. A case–control study compares the character-
istics of patients with and without a specific disease. The Cytosponge is a small capsule-
encased sponge that is attached to a string. The capsule rapidly dissolves in the stomach
after being swallowed, and the sponge collects esophageal cells for TFF3 staining when it is
retrieved by pulling on the string.
What Did the Researchers Do and Find?
The researchers enrolled 463 individuals attending 11 UK hospitals for investigational
endoscopy for dyspepsia and reflux symptoms as controls, and 647 patients with Barrett's
esophagus who were attending hospital for monitoring endoscopy. Before undergoing en-
doscopy, the study participants swallowed a Cytosponge so that the researchers could eval-
uate the safety, acceptability, and accuracy of the Cytosponge-TFF3 test for the diagnosis
of Barrett's esophagus compared with endoscopy. Nearly 94% of the participants swal-
lowed the Cytosponge successfully, there were no adverse effects attributed to the device,
and those participants that swallowed the device generally rated the experience as accept-
able. The overall sensitivity of the Cytosponge-TFF3 test (its ability to detect true positives)
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was 79.9%. That is, 79.9% of the individuals with endoscopically diagnosed Barrett's
esophagus were identified as having the condition using the new test. The sensitivity of the
test was greater among patients who had a longer length of affected esophagus and impor-
tantly was not reduced in patients with dysplasia. Compared to endoscopy, the specificity
of the Cytosponge-TFF3 test (its ability to detect true negatives) was 92.4%. That is, 92.4%
of people unaffected by Barrett's esophagus were correctly identified as being unaffected.
What Do These Findings Mean?
The case–control design of this study means that its results are not generalizable to a pri-
mary care population. Also, the study used only a single measure of the acceptability of the
Cytosponge-TFF3 test, Nevertheless, these findings indicate that this minimally invasive
test for Barrett's esophagus is safe and acceptable, and that its accuracy is similar to that of
colorectal cancer and cervical cancer screening tests. The Cytosponge-TFF3 test might,
therefore, provide a simple, inexpensive way to identify those patients with reflux symp-
toms who warrant endoscopy to diagnose Barrett's esophagus, although randomized con-
trolled trials of the test are needed before its routine clinical implementation. Moreover,
because most people with Barrett's esophagus never develop esophageal cancer, additional
biomarkers ideally need to be added to the test before its routine implementation to identi-
fy those individuals who have the greatest risk of esophageal cancer, and thereby avoid
overtreatment of Barrett's esophagus.
Additional Information
Please access these websites via the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001780.
• The US National Institute of Diabetes and Digestive andKidney Diseases provides de-
tailed information about Barrett's esophagus and gastroesophageal reflux disease
• The US National Cancer Institute provides informationfor patients and health profes-
sionals about esophageal cancer (in English and Spanish)
• Cancer Research UK (a non-profit organization) provides detailed information about
Barrett's esophagus (including a video about having the Cytosponge test and further
information about this study, the BEST2 Study) and about esophageal cancer
• The UK National Health Service Choices website has pages on the complications of
gastroesophageal reflux and on esophageal cancer (including a real story)
• Heartburn Cancer Awareness Support is a non-profit organization that aims to improve
public awareness and provides support for people affected by Barrett's esophagus; the
organization's website explains the range of initiatives to promote education and aware-
ness as well as highlighting personal stories of those affected by Barrett's esophagus and
esophageal cancer
• The British Society of Gastroenterology has published guidelines on the diagnosis and
management of Barrett's esophagus
• The UK National Institute for Health and CareExcellence has published guidelines for
gastroesophageal reflux
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• The Barrett's Esophagus Campaign is a UK-based non-profit organization that supports
research into the condition and provides support for people affected by Barrett's esopha-
gus; its website includes personal stories about the condition
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